Bicycle Therapeutics has appointed a Chief Medical Officer. 

Dr. Dominic Smethurst has joined the Cambridge company, which is developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. 

Dr. Smethurst brings extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases. 

He has more than 20 years of experience working with leading pharmaceutical and biotechnology companies, clinical research institutions and the NHS. 

Among his previous roles are Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche.  

“Given his in-depth knowledge of conventional and disruptive therapeutic modalities, we believe Dominic is uniquely qualified to guide development of Bicycles as potential solutions to many of the limitations faced by small molecule and antibody-based medicines,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.  

“Dominic will be responsible for designing and driving execution of the clinical development plans for our pipeline candidates, all of which currently represent possible first-in-class or best-in-class therapies.  

“Dominic adds a critical capability to our senior leadership team, and we are pleased to welcome him to Bicycle.” 

In June Bicycle announced the appointment of Sir Keith Peters FRS to chairman of the firm’s scientific advisory board.  

Despite its Cambridge headquarters, many key functions and members of its leadership team are located in the US.